Model TCB006 - B7-H4 CAR-T

TCB006 is an allogeneic CAR-T product targeting B7-H4 for the treatment of cancers arising from solid tumors. B7-H4 antigen is overexpressed in breast cancers, especially triple negative breast cancer, and ovarian cancers, both diseases with acute clinical needs. There are 270,000 new cases of breast cancer and 23,000 new cases of ovarian cancer per year in the US. It is also implicated in cancers associated with infection by Epstein-Barr Virus (EBV). Previous efforts to target B7-H4 expression have been limited by off-tumor toxicity which makes it an ideal candidate for GDTs with a Co-stim CAR. Additionally, B7-H4 is a potential cancer stem cell marker in esophageal squamous cell carcinoma – this may permit targeting of the tumor initiating compartment.